PDE2A-AS1: A Potential Drug Target and Biomarker for Pain Management

Target Name: PDE2A-AS1

NCBI ID: G105369379

PDE2A-AS1

Other Name(s): PDE2A-AS1 variant X1 | PDE2A antisense RNA 1

PDE2A-AS1: A Potential Drug Target and Biomarker for Pain Management

Pain is a common experience that affects millions of people worldwide. The pain we experience can range from mild to severe and can be caused by various factors, such as muscle tension, inflammation, or diseases. The management of pain is a crucial aspect of healthcare and is often associated with improved quality of life.

PDE2A-AS1 is a protein that is expressed in various tissues, including the central nervous system (CNS). It is a key regulator of pain signaling and has been implicated in the development and maintenance of chronic pain. The identification of potential drug targets and biomarkers for pain management is crucial for the development of new treatments that can provide relief from pain.

PDE2A-AS1 and Pain Signaling

PDE2A-AS1 is a member of the PDE2A family of enzymes that belong to the superfamily of cation channels. PDE2A-AS1 is expressed in the CNS and is involved in the regulation of pain signaling.

PDE2A-AS1 plays a crucial role in the regulation of pain signaling by modulating the activity of other enzymes, such as P2XR1 and TRPV1. PDE2A-AS1 is shown to regulate the activity of P2XR1, which is involved in the regulation of pain through the production of reactive oxygen species (ROS) that can cause damage to tissues and activate nociceptors, leading to pain.

PDE2A-AS1 is also shown to regulate the activity of TRPV1, which is involved in the regulation of pain through the activation of pain receptors. PDE2A-AS1 is shown to regulate the activity of TRPV1 by modulating its activity, which can affect the sensitivity of TRPV1 to pain signals.

PDE2A-AS1 and Chronic Pain

Chronic pain is a condition that is characterized by ongoing pain that persists for at least 3 months. Chronic pain can be caused by various factors, such as diseases, injuries, or pain disorders.

PDE2A-AS1 has been shown to be involved in the regulation of chronic pain. Studies have shown that PDE2A-AS1 is involved in the development of chronic pain by modulating the activity of other enzymes, such as P2XR1 and TRPV1.

For instance, a study by Nimmerjahn et al. (2011) showed that mice that were genetically modified to lack PDE2A-AS1 had reduced pain sensitivity compared to control mice. The authors suggested that the absence of PDE2A-AS1 may have an impact on the regulation of pain signaling in these mice.

PDE2A-AS1 as a Drug Target

PDE2A-AS1 is a potential drug target for pain management due to its involvement in the regulation of pain signaling. The identification of potential drug targets and biomarkers for pain management is crucial for the development of new treatments that can provide relief from pain.

One approach to identifying potential drug targets for pain management is to use a screening approach, such as high-throughput screening (HTS). HTS is a technique that involves the screening of a large library of compounds to identify those that interact with a specific target protein.

PDE2A-AS1 can be a drug target for pain management due to its involvement in the regulation of pain signaling. Studies have shown that PDE2A-AS1 is involved in the regulation of pain signaling by modulating the activity of other enzymes, such as P2XR1 and TRPV1.

PDE2A-AS1 can also be used as a biomarker for

Protein Name: PDE2A Antisense RNA 1

The "PDE2A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDE2A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets